Spyre Therapeutics' CEO Sells 15,000 Shares This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing.
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
